Email this article Cyclophosphamide efficacy inmaintenance therapy of nephrotic syndrome in patients withchronic glomerulonephritis
- Authors: Duman VL1, Shkerina LI1
-
Affiliations:
- Уральская государственная медицинская академия
- Issue: Vol 79, No 9 (2004)
- Pages: 26-28
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/29883
- ID: 29883
Cite item
Full Text
Abstract
Mm. To study effects of cyclophosphamide (CP) on duration of remission in chronic glomerulonephritis (CGN) with nephrotic syndrome (NS).
Material and methods. Achievement of complete remission of NS was followed by intravenous treatment with CP in 25 of 28patients. 20 patients were in remission for 7-90 months (mean 38.9 ±5.6
months). NS recurred in 8patients after remission duration from 3 to 48 months (mean 25.4 ±6.1
months).
Results. Patients in remission and NS recurrence were comparable by morphology of CGN, gender,
CGN history, start of CP treatment, accumulated CP dose at remission induction, 24 h protein urine
loss, levels of immunoglobulins, C-reactive protein, fibrinogen, seromucoid, complement titer, circulating immune complexes. Significant differences were observed in duration of CP maintenance, accumulated dose within the first three months and maintenance therapy.
Conclusion. CP maintenance in CGN with NS should be conducted as an intravenous pulse-therapy
once in 3 weeks for 3 months than once in 1-3 months for 1.5-2 years.
Material and methods. Achievement of complete remission of NS was followed by intravenous treatment with CP in 25 of 28patients. 20 patients were in remission for 7-90 months (mean 38.9 ±5.6
months). NS recurred in 8patients after remission duration from 3 to 48 months (mean 25.4 ±6.1
months).
Results. Patients in remission and NS recurrence were comparable by morphology of CGN, gender,
CGN history, start of CP treatment, accumulated CP dose at remission induction, 24 h protein urine
loss, levels of immunoglobulins, C-reactive protein, fibrinogen, seromucoid, complement titer, circulating immune complexes. Significant differences were observed in duration of CP maintenance, accumulated dose within the first three months and maintenance therapy.
Conclusion. CP maintenance in CGN with NS should be conducted as an intravenous pulse-therapy
once in 3 weeks for 3 months than once in 1-3 months for 1.5-2 years.
About the authors
V L Duman
Уральская государственная медицинская академияУральская государственная медицинская академия
L I Shkerina
Уральская государственная медицинская академияУральская государственная медицинская академия
References
- Ponticelli С, Altieri P., Scolari F. et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 1998; 9 (3): 444- 450.
- Arslan S., Saatci U., Ozen S. et al. Membranoproliferative glomerulonephritis in childhood: factors affecting prognosis. Int. Urol. Nephrol. 1997; 29 (6): 711-716.
- Inaba S., Tanizawa Т., Takahashi T. et al. Decrease of mesangial matrix after immunosuppressive therapy in children with reversible membranoproliferative glomerulonephritis type I. Clin. Nephrol. 1996; 45 (40: 217-225.
- Pal K., Nagy J. Mesangiocapillary glomerulonephritis. Orv. Hetil. 1996; 137 (26): 1403-1407.
- Cattran D. C, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J. Kidney Dis. 1998; 32 (1): 72-79.
- Ponticelli C, Villa M., Banfl G. et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am. J. Kidney Dis. 1999; 34 (4): 618-625.
- Думан В. Л. Терапевтический эффект циклофосфамида у больных хроническим гломерулонефритом с нефротическим синдромом. Тр. арх. 2002; 6: 39-41.
- Faedda R., Pirisi M., Satta A. et al. Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions. Clin. Nephrol. 1996; 46 (4); 237-244.
- Branten A. J., Reichert L. J., Koene R. A., Wetzels J. F. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Quart. J. Med. 1998; 91 (5): 359-366.
- Gourley M. F., Austin H. A. 3rd, Scott D. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 1996; 125 (7): 549-557.
- Funauchi M., Ikoma S., Sugiyama M. et al. Crossroads of the effects of cyclophosphamide pulse therapy for lupus nephritis experience of 11 cases. J. Clin. Lab. Immunol. 1998; 50 (2): 45-54.
- Niaudet P. Treatment of lupus nephritis in children. Pediatr. Nephrol. 2000; 14 (2): 158-166.
- Тареева И. Е., Шилов Е. М., Краснова Т. Н. Лечение гломерулонефритов. М.: Novartis, 2000.
- Краснова Т. Н., Шилов Е. М., Тареева И. Е. и др. Сравнение двух методов лечения циклофосфаном больных хроническим гломерулонефритом с нефротическим синдромом. Тер. арх. 1998; 6: 14-17.
Supplementary files
